Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

UMSC 01

Next Previous
Drug Profile

UMSC 01

Alternative Names: Allogeneic umbilical cord mesenchymal stem cells - Ever Supreme Bio Technology; Umbilical cord-derived stem cells - Ever Supreme Bio Technology; UMC-01; UMSC-01

Latest Information Update: 04 Dec 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator China Medical University Hospital
  • Developer Ever Supreme Bio Technology
  • Class Mesenchymal stem cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Myocardial infarction
  • Phase I/II COVID 2019 infections; Multiple sclerosis
  • No development reported Ischaemic stroke

Most Recent Events

  • 24 Sep 2023 Phase-II clinical trials in Myocardial infarction (Treatment-experienced, Adjunctive treatment) in Taiwan (Intracoronary) (NCT06147986)
  • 24 Sep 2023 Phase-II clinical trials in Myocardial infarction (Treatment-experienced, Adjunctive treatment) in Taiwan (IV)
  • 28 Jun 2023 No recent reports of development identified for phase-I development in Ischaemic stroke in Taiwan (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top